Initiation and promotion at different ages and doses in 2200 mice. III. Linear extrapolation from high doses may underestimate low-dose tumour risks. by Stenbäck, F. et al.
Br. J. Cancer (1981) 44, 24
INITIATION AND PROMOTION AT DIFFERENT AGES AND
DOSES IN 2200 MICE
III. LINEAR EXTRAPOLATION FROM HIGH DOSES MAY
UNDERESTIMATE LOW-DOSE TUMOUR RISKS
F. STENBACK*, R. PETOt AND P. SHUBIKt
From the Eppley Institute for Cancer Research, Omaha, Nebraska
Received 29 April 1980 Accepted 27 AMarchi 1981
Summary.-The dose-response relationships fromthe data described in Paper I were
analysed. Among unpromoted animals, only doses sufficient to cause ulceration with
subsequent promotion due to wound healing caused a rapid crop of tumours, so the
dose-response curve exhibited strong upward curvature. Among promoted animals,
the response of the skin to initiation appeared to have been nearly saturated by all
DMBA doses tested, so that a30-fold decrease in dose produced only a 3-fold decrease
in effect. The dose-response relationship thus exhibited strong downward curvature.
Among promoted animals, estimation of the risks associated with very low doses
of carcinogen by linear extrapolation through the origin from the effects of larger
doses (which is often assumed to be conservative) would under-estimate the true risks
by 10-fold or more. Our results emphasize that whereas linear interpolation from the
results ofhigh doses may be reasonable for data on the effects ofcontinuous treatment
with non-toxic dose levels of carcinogen, it may be misleading when extrapolating,
as here, from the effects of single large doses.
Thesiynificance ofdowvnward curvature.
The study of dose-response relationships
is of interest for two reasons. First, the
nature of the dose-response relationship
may shed some light on the biological
processes involved in carcinogenesis. For
example, some hypotheses about cancer
mechanisms predict an approximately
linear dose response (i.e. proportionality
between dose and number of tumours)
while most others predict some upward
curvature in the dose-response graph (i.e.
that doubling the dose would more than
double the effect). If downward curvature
were demonstrated, this would exclude a
large class of previously plausible hypo-
theses.
Second, because of the need to promul-
gate government regulations for various
carcinogens, there is currently much dis-
pute as to the magnitude of the risk likely
to be associated with human exposure to
lower doses of various carcinogens than
can be studied in practicable experimental
or epidemiological investigations. Some
authors (e.g. Guess et al., 1977; Crump
et al., 1976; Peto, 1979) have urged that a
clear distinction be made between "one-
shot" experiments (in which the effects
ofa single, usually toxic dose ofcarcinogen
are studied) and "continuous" experi-
ments (studying the effects of repeated
doses, each insufficient separately or
together to alter materially the cellular
architecture of the target tissue). These
authors have argued first, that even if no
useful general rules emerge about the
shapes of the dose-response relationships
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in one-shot experiments, nevertheless there
is generally likely to be either linearity or
upward curvature in the relationship
between cancer risk and dose rate in
continuous experiments; and second, that
for continuous experiments linear extra-
polation downwards is generally therefore
either correct or conservative, but should
rarely if ever seriously under- estimate
the risk of cancer under conditions of low-
dose continuous carcinogenesis. Various
other authors (e.g. Mantel & Schneider-
man, 1975, or Cornfield, 1977) have,
however, propounded arguments that
linear extrapolation may almost always
seriously over-estimate cancer risks at
low doses, although these authors have
not distinguished clearly between one-shot
and continuous experiments. For a few
carcinogens (particularly radiation) most
of the animal and human data derives
from one-shot studies (i.e. from animals or
people exposed quickly to tens or hundreds
of rads). Consequently, there is a need to
determine whether the general rule of
linearity or sublinearity (i.e. upward
curvature) of dose-response relationships
which is widely accepted for continuous
carcinogenesis also applies to one-shot
carcinogenesis. If it is incorrectly assumed
to do so then human risks from low doses
of such agents may be underestimated
even by linear extrapolation, while any
of the mathematical models (e.g. the
"threshold", "virtually safe dose" or
"probit" models) which assume upward
curvature would lead to even more
serious underestimates ofrisk. The present
study suggests that this may on occasion
be the case. (Note that, in this paper,
"linear" extrapolation always means linear
extrapolation towards zero extra risk at
zero dose, i.e. proportionality of effect.)
METHODS
Each of the 9 combinations of age at
initiation and age at promotion described in
the accompanying paper (Stenback et al.,
1981) was studied with initiating doses of
10, 30, 100 or 300 ,ug ofDMBA. Consequently,
within each group we may derive a dose-
response relationship. Although any single
such dose-response relationship may be
somewhat unstable due to the limited number
(40-80 mice) of mice at each of the 36 dose x
time combinations studied, when the 9 dose-
response relationships are averaged, a reliable
and meaningful pattern should emerge. Since
in many groups there was a substantial delay
between initiation and promotion, we can
examine two completely separate dose-
response curves:
(a) the relationship between initiating dose
and the response to promotion, when pro-
motion does eventually occur, and
(b) the relationship between initiating dose
and the number of tumours that arise soon
after initiation in the absence of TPA pro-
motion (due, perhaps, to the promotional
effects of the healing of the ulcers and
erosions caused by some DMBA doses).
In each case we may assess response by
any 1 of4 different indices ofcancerincidence,
.e.
(i) the total nunmber of tumours arising
within a particular 20-week period of time
(to which one mouse may contribute more
than one tumour, which makes the calcula-
tion ofreliable P values difficult), or
(ii-iv) thenumberoftumour-bearinganimals,
i.e. by a standard time-to-first-tumour ana-
lysis, with P values, of (ii) any tumour, irres-
pective of size or type, or (iii) 10mm tumours,
or (iv) malignant tumours.
Details of the experimental and statistical
methods are given in the accompanying
paper by Stenbiack et al. (1981).
RESULTS
The dependence on initiating dose of the
effects of promotion
No matter which index of response is
adopted (small tumours, large tumours or
malignant tumours), Fig. 1 shows clearly
that the response to promotion exhibits
striking downward curvature, the yield
following initiation with only 10 ,ug being
one-third of the yield with 300 ,ug, not
one-thirtieth of it or less. (For numerical
details, see Appendix Tables a and b.)
In other words, estimation of the cancer
yield from 10 ,ug by linear extrapolation
downward from the yield at 300 ,ug would
underestimate the true risk of the lower
dose by a factor of about 10. If there were
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FIG. 1.--Tumour response: O/E values giving dose-response relationships (lutring promotion (from
Appendix Tables a and b. * All tumours within 20 weeks. 0 First tumours of any size or type
(witli approximate 95%O conficlence intervals). O First 10mm tumours. A First malignant tumour.
very marked genetic heterogeneity then
this could produce a "shoulder" like those
seen in Fig. 1 in the dose-response rela-
tionship for time tofirst tumour. However,
if the intensity of effect is proportional to
dose and the test animals do comprise a
mixture of highly susceptible and very
resistant genotypes, the affected animals
might each have been expected to develop
many tumours in response to the higher
doses tested, and they did not. (Indeed
there is at least as marked a shoulder in
the O/E values for total tumours in Fig. 1
as in the O/E values for the numbers of
tumour-bearing animals.) Moreover, even
if we restrict our attention to the two
lowest doses (10 jug and 30 ,ug) which do
not suffice to cause much skin erosion or
ulceration, we find that the yield from
10 jug exceeds one-third of the yield from
30 ig. It is as though even 10 tag suffices
to initiate almost all the cells that are
available to be initiated. It should be
remembered that the doses given were
administered in only 0-017 ml acetone,
and so remained in an area probably less
than 0 5 cm2, so the lowest initiating
stimulus we tested was well over 20 ,ug/
cm2, which is quite high. (To achieve this
DMBA dose per unit area over the whole
back of the mouse would require a dose of
some hundreds ofmicrograms ofDMBA in
0-2 ml of acetone.) The shape of the dose-
response relationship at DMBA concentra-
tions lower than the 20 or more 1jg/CM2,
which was the lowest dose we studied,
cannot of course be inferred directly from
our data, but presumably at some lower
dose per unit area the response that will
be elicited by promotion must start to
decrease in proportion to the DMBA dose.
In Fig. 2 the life-table estimates (Pike
& Roe, 1963; IARC, 1980) ofthe probabili-
ties of tumourless animals remaining
tumourless at various times after promo-
tion are plotted, pooling all promoted
animals irrespective of protocol. This is
subject to some slight biases, as the pro-
portions promoted at different times are
different in the high- and low-dose groups,
but it does illustrate adequately the lack
of a 30-fold increase in the effects on
initiation of increasing the dose from
10 jtg to 300 jug of DMBA.
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Fic. 2. Relationship between (lose of initiator and time to first tumour after start of promotion.
Life-table estimate of nev-er having hadl a tumour of any type. Data for the aggregate of all pro-
mote(l animals (irrespective of ages at initiation or at promotion).
The dependence oftumour yield oninitiating
dose at age 8 weeks in the absence of pro-
motion with TPA
Because, in many of our groups, there
was a long interval between the single
initiating dose of DMBA and subsequent
promotion, we can use the observations
made in these intervals to characterize the
dose-response relationship for the tumori-
genic effects of a single unpromoted dose
of DMBA. The use of life-table techniques
(Pike & Roe, 1963; IARC, 1980), treat-
ing animals as lost to observation when
their TPA begins, allows us to pool the
experience of several hundred animals in
many different groups, and our life-table
estimates of the tumorigenic effects of
single doses of DMBA in 0 017 ml of
acetone are therefore, initially at least,
extremely reliable.
Fig. 3 illustrates the response, in terms
of time to first tumour (of any size or
type) to different single doses of DMBA
administered at age 8 weeks. Althoiugh the
pool of all groups of animals being ob-
served after DMBA alone was depleted
at 11, 18, 31, 51, and 71 weeks of age by
mice being withdrawn in order to be pro-
moted, there remained, at each DMBA
dose level, over 200 mice at 31 weeks. In
the absence of TPA no tumours arose in
animals given 10 ug or 30 [kg DMBA before
Week 31, while a quarter to a third of the
animals receiving 100 /tg or 300 jug of
DMBA developed tumours, presumably
because of the promotional effects of the
healing of DMBA-induced erosions and
ulcers. This reproduces the findings of
Turusov et al. (1971) that a single un-
promoted DMBA dose of 200 jug in
0 033 ml of solvent caused severe necrosis
with ulceration and scarring, with a
quarter of the mice developing tumours
within 32 weeks, but that doses of 100 jug
or less in 0 033 ml of solvent did not cause
severe necrosis nor any tumours within
6 months in the absence of promotion.
(100 jug in 0 033 ml yields a concentration
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FIG. 3.-Tumours without promotion. Life-table estimate of probability of never having had a
tumour of any type. Data for aggregate ofall animals initiated at age 8 weeks (treatment schedules
b, c, d and e: animals scheduled to be promoted some time after they were initiated contribute to
this graph only up to the time when they began to be promoted).
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FIG. 4.-lOmm tumours without promotion. Life-table estimate of probability of never having had a
lOmm tumour. Data for aggregate of all animals initiated at age 8 weeks (treatment schedules
b, c, d and e: animals scheduled to be promoted some time after they were initiated contribute to
this graph only up to the time when they began to be promoted).
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per unit area of skin intermediate between
our (loses of 100 jug an(I 30 jug in 0 017 ml).
Likewise, Terracini et al. (1960) found that
single tlnpromote(d doses of 50, 1 00 an(d
200 pg DMBA in 0-05 ml acetone yielded
ulcers in 00/, 2a5% and 75o/% of animals,
and yieldledl tumours withini 30 weeks in
0/22, 5/55 andl 28/50 of the animals in
these groups. rhese author.s particularly
note(I that the tu:mours often arose from
the ulcers or other less extreme skin
lesions.
Many of the early tuimoutrs which we
observed following DMBA alone regressed
when the healing process was complete,
and niever became large. But, as time went
by, quite sutbstantial nuimbers of 10 mm
ttumouLrs appeared (Fig. 4) among the
unpromoted animals at the two higher
doses, and many killed their hosts. By
contrast, no 10mm ttumours arose withotit
promotion at the two lower dose levels
(thoughi 3 smaller mnalignancies did arise
just before promotion cut observation of
the animals short). Again, this finding
reproduices the results of Terracini et al.
(1960).
The dependence on initiatinyj dose at 48
w-eeks of tumnour yield in the absence of
promotion with TP'A
Among animals initiated at 48 weeks
and inot promoted for 23 weeks thereafter,
there were somewhat more tttnours at the
top dose than alt the top dose among
animals initiated at 8 weeks. SurprisinglI,
however, the mnarke(d discontinuity in the
(lose-response relationship which Terra-
cini et al. (19960), Turusov et al. (1971) and
ourselves had found among animals
initiated at 8 weeks was no longer evident,
and even the lower two doses (10 and 30
[kg DMBA) (lid elicit some tuimours (not
illustrated; numnierical details in Appendix
Table c). We do not know why no dis-
continuity is evident at 48 weeks. One
obvious suggestion is that the likelihood
of erosion or ulceration in response to a
given 1)MBA close mnay differ at 8 and at
48 weeks, or that the rate of (promotional)
healing of such lesiotns mav differ. Records
ofthe apparent extent and rate ofrecovery
of erosion or ulceration caused by un-
promoted initiation at 48 weeks might
have helped eluicidate this point, but un-
forttunately stuch records are_ no longer
available. In an in(lependent replication
of our 48-week study of unpromoted
initiation (using animals of the same sex
an(I strain, but from a different souirce),
200 mice were randomized, 50 to a group,
between initiation with 1O, 30, 100 or 300
Mg DMBA in 0-017 ml acetone, and they
were then observed for 50 more weeks.
This more recent experimenit reproduced,
for initiation at 48 weeks, the dichotomous
split between the two high doses and the
two low doses, as seen in Figs 2, 3 and 4,
and we therefore consider this, and not the
response pattern in Appendix Table c, to
be typical.
D)ISCUSSION
Initiation wcithout promiotion
It is not suirprising that, at least among
animals initiated at 8 weeks of age, there
is a very great difference in the immediate
responses to 30 Mug and to 100 Mkg of un-
promoted initFiation, for 30 Mug in 0*017 ml
ofsolvent rarely causes ulceration, whereas
100 Mg in the same volume usually does so.
Active healing processes undoubtedly have
a promotional effect on mouise skin for
example, in this experiment it was often
noticed that papillomas arose precisely
out of the very thin line of epithelial cells
overgrowing a DMBA-induced scar, and
Terracini et al. (1960) report similar obser-
vations.
What is perhaps more interesting is the
finding that the number of 10mm tumours
arising 9-12 months after uinpromoted
initiation should exhibit the same dis-
continuity. This suggests that early pro-
motion, either by woun(l healing or by
TPA, can irreversibly "fix" certain cells
(or microscopic clones of cells) in a higher
risk category. In multistage terminology,
this might be described as progression to
a later "stage" of neoplasticdevelopment).
If there is indeed an irreversible cellular
effect which can be produced by brief
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promotion, the simple dichotomy between
normal cells and initiated cells will need
to be extended to allow various categories
of initiated cells (or microscopic clones of
cells), and promotion itself may prove to
be a multi-step process, as was suggested
by Boutwell (1964) and Slaga et al. (1980).
Initiation w)ith promotion
The downward curvature of the dose-
response curve indicates that the gen-
eralizations about "conservative" risk
estimation by linear extrapolation which
have been proposed for continuous-car-
cinogenesis experiments cannot necessarily
be carried over to single-dose experiments.
This emphasizes the particular need to
check the assumptions of linearity under-
lying the setting of safety levels for radia-
tion exposure, since so much radiation
data come from single-dose studies.
The reasons for such a dose-response
relationship in the present context are
unclear, especially since for another poly-
aromatic hydrocarbon, benzo(a)pyrene,
Pereira et al. (1979) have shown simple
proportionality between the dose applied
to mouse skinandtheamountsubsequently
bound to the epidermal DNA. One possible
explanation is that even our lowest dose
(20-50 tZg/cm2) sufficed to initiate nearly
all the available target cells, and another
is that higher doses actually kill off many
of the initiated cells. Both are made
plausible by other observations. Mondal &
Heidelberger (1970) have shown in vitro
that they can "transform" most of a
population of cultured mammalian cells
with MCA, and Kennedy et al. (1980)
and Kennedy & Little (1980) have shown
in vitro that they can "initiate" most
of a population of cultured mammalian
cells with an X-ray dose of 100 rad. Major
& Mole (1978) have shown that if mice
irradiated with 100 rad are randomized
between getting and avoiding a further
such dose of X-rays, those which get a
further dose are less likely to develop
leukaemia, presumably because the second
dose kills more preleukaemic cells than it
generates. Finally, returning to DMBA on
mouse skin, it has been shown that 100
doses of 1 jtg ofDMBA, given twice weekly
are nmuch more tumorigenic than a single
dose of 100 jig (Saffiotti & Shubik, 1956),
which again is what would be expected
if small doses suffice to initiate almost all
the cells which are temporarily at risk of
initiation.
In retrospect, since we believe that we
did saturate the possible response of the
mouse skin, we do not recommend that
future workers treat such a small area of
the back of the mouse as we did. Using a
volume of solvent sufficient to spread over
the whole shaved back, at dose levels per
unit area which are sufficiently low not to
saturate the possible response of the skin,
(i) will avoid any complication due to
promotional wound healing;
(ii) will allow any factors modifying the
efficacy of DMBA to be measured; and
(iii) will cause more target cells to be
exposed, which will improve the statis-
tical accuracy ofthe results.
Ifsuch doses do not produce highenough
tumour yields, it would perhaps be better
to study initiation by a few weekly very
low doses rather than by single substantial
doses.
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TABLE c.-Numbers oftumours arising without TPApromotion within 23 weeksofinitiation
for animals initiated at 8 or 48 weeks of age
300,ug 100 ug 30 ,ug 10 tg
initiation initiation initiation initiation
Age at , , ,
initiation 0 MS 0 MS 0 MS 0 MS
8 weeks 94 221 66 211 0 210 0 214
043 T/M 0-31 T/M 0.00 T/M 0 00 T/M
48 weeks 46 55 10 59 6 63 2 72
0-84 T/M 0-17 T/M 0-10 T/M 0 03 T/M
MS=Number of Mice Surviving at least 23 weeks after initiation.
0=Number of tumours, irrespective of size or type, Observed to arise on these survivors during the 23
weeks following initiation.
T/M =Tumours per mouse =O/MS.